A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-Facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals

EClinicalMedicine - United Kingdom
doi 10.1016/j.eclinm.2018.12.006

Related search